Deutsche Bank lowers its target price to $105 from $116 on Buy-rated Shire PLC SHPGY as PREVENT 2 failed to meet primary end points.
Deutsche Bank notes, "Shire announced that PREVENT 2 – one of the two Ph 3 studies on Lialda for the treatment of diverticulitis – did not meet its primary endpoint of reduction in the rate of recurrence over a two year period. While there is another trial (PREVENT 1) that will read out later this year, the co has decided not to pursue a regulatory filing for this indication at this time."
SHPGY closed at $94.75 a share on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in